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ABSTRACT
Dedifferentiated chondrosarcoma (DDCS) is a rare disease with a dismal prognosis.
DDCS consists of two morphologically distinct components: the cartilaginous and
noncartilaginous components. Whether the two components originate from the same
progenitor cells has been controversial. Recurrent DDCS commonly displays increased
proliferation compared with the primary tumor. However, there is no conclusive
explanation for this mechanism. In this paper, we present two DDCSs in the sellar
region. Patient 1 exclusively exhibited a noncartilaginous component with a TP53
frameshift mutation in the pathological specimens from the first surgery. The tumor
recurred after radiation therapy with an exceedingly increased proliferation index.
Targeted next-generation sequencing (NGS) revealed the presence of both a TP53
mutation and a PTEN deletion in the cartilaginous and the noncartilaginous components
of the recurrent tumor. Fluorescence in situ hybridization and immunostaining confirmed
reduced DNA copy number and protein levels of the PTEN gene as a result of the PTEN
deletion. Patient 2 exhibited both cartilaginous and noncartilaginous components in the
surgical specimens. Targeted NGS of cells from both components showed neither TP53
nor PTEN mutations, making Patient 2 a naïve TP53 and PTEN control for comparison.
In conclusion, additional PTEN loss in the background of the TP53 mutation could be
the cause of increased proliferation capacity in the recurrent tumor.
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INTRODUCTION

RESULTS

Dedifferentiated chondrosarcoma (DDCS) is
an uncommon type of chondrosarcoma with a peak
incidence at 60 to 70 years of age [1]. The most
frequently affected locations include the femur,
pelvis, humerus and scapula. Skull involvement is
extremely rare [1]. Morphologically, there are two
distinct components. The cartilaginous component
is characterized by well-differentiated chondrocytelike tumor cells. In contrast, the noncartilaginous
dedifferentiated component is characterized by spindleshaped neoplastic cells [2]. DDCS can be further
categorized into two subtypes based on the relationship
between the two components. In the classical subtype
[3, 4], the two components typically exhibit a sharp
boundary with no transitional zone, whereas a clear
transitional zone between the two components is
observed in the non-classical type [4].
The histogenesis of DDCS remains unclear.
More specifically, the origins of the cartilaginous and
noncartilaginous components of DDCS remain unknown.
Two theories exist with regard to the origins of the
disease. The collision tumor theory [3, 5] states that each
component originates separately from different progenitor
cells. In contrast, the competing theory maintains that
both components originate from the same progenitor cells
and share common chondrosarcoma-associated somatic
mutations [4, 6].
There is a dismal prognosis for this disease, for
which surgical intervention remains the mainstay for
treatment [1]. The value of chemotherapy remains
questionable [7]. Previous studies indicate that DDCS
might recur in the presence or absence of radiation
therapy [2]. As previously reported [6, 8], the Ki-67
proliferation index increased when chondrosarcoma
recurs; however, the mechanism remains unresolved.
Previous studies [8, 9] have identified several frequent
genetic mutations in DDCS, including IDH1, IDH2, and
TP53. TP53 gene deregulation has long been suggested
as a causative factor for DDCS. The TP53 protein is
frequently overexpressed in DDCS [4, 10, 11]. However,
TP53 alone cannot explain the increased Ki-67 index.
Additional genetic or epigenetic events might account
for the more rapid progression.
In this paper, we present two patients of DDCS
in the skull region after radiation therapy. We used
targeted next-generation sequencing (NGS) technology
[12-15] to sequence a panel of genes in an attempt to
discover targetable genetic changes and to decipher the
pathogenesis of increased proliferation capacity in the
recurrent tumor.

Medical history, radiographic findings,
treatment and pathologic findings
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Patient 1
This patient was a 28-year-old man who was
admitted to a local hospital due to headache and diplopia.
Magnetic resonance imaging (MRI) revealed a 2.8 x 1.9
x 1.8 cm-sized mass with homogeneous enhancement in
the sellar region after gadolinium injection (Figure 1A).
The patient underwent a trans-sphenoidal surgery at
that hospital. Hematoxylin and eosin (H&E) staining of
the resected tumor tissue (Patient-1-surgery-1 or P1-S1)
revealed that the tumor cells had a spindle shape without
any chondrocytic tumor cells. No tumor cells showed
S-100 positivity by immunostaining (Figure 1B). No
positivity was noted for neuron-specific enolase (NSE),
glial fibrillary acidic protein (GFAP), epithelial membrane
antigen (EMA), or actin in the tumor cells (data not
shown). Therefore, no definitive diagnosis, except for a
spindle cell tumor, was reached in the local hospital.
One month later, MRI detected tumor relapse,
possibly derived from the remnant tumor cells. The patient
then underwent a Gamma knife radiosurgery with a dose
of 1260 cGy to the tumor region (50% isodose curve) at
the local hospital in an attempt to control the recurrent
tumor. Unfortunately, 4 months after the Gamma knife
radiosurgery, the patient exhibited progressive decline
in visual acuity, severe headaches and blepharoptosis.
The patient was then transferred to our hospital, and
MRI demonstrated a 3.0 x 4.8 x 3.5 cm irregular sellar
cystic mass with ring-enhancement after gadolinium
injection (Figure 1A). Both fluorodeoxyglucose (FDG)
and tetraazacyclododecane tetraacetic acid–octreotate
(DOTATATE) positron emission tomography (PET) images
exhibited similar ring-shaped tracer uptake (Figure 1C).
The patient then underwent a trans-sphenoidal surgery. The
pathological specimen was defined as Patient-1-surgery-2
(P1-S2). H&E staining revealed both cartilaginous (P1-S2
cart) and noncartilaginous (P1-S2 noncart) components
(Figure 1A). A clear transitional zone was noted between
the two components, resembling the non-classical type
DDCS. The cartilaginous cells exhibited S-100 positivity
by immunohistochemical staining (Figure 1B), whereas
the noncartilaginous component did not (data not shown).
Both components exhibited vimentin positivity, indicating
a mesenchymal origin (Figure 1B). CD68 staining was
positive in a portion of the cells, most likely the intermixed
histiocytes (Figure 1B). The P1-S2 noncartilaginous
component exhibited a similar morphology to the tumor
cells in P1-S1, indicating that P1-S2 might originate from
the remnant tumor cells from P1-S1.
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Figure 1: A. H&E staining and enhanced MRI of Patient 1. The surgical specimen from the first surgery showed only noncartilaginous
spindle-shaped tumor cells (P1-S1, upper panel). The surgical specimen from the second surgery exhibited both cartilaginous (P1-S2 cart)
and noncartilaginous (P1-S2 noncart) neoplastic components (lower panel). B. Representative immunostaining images for S-100 in P1S1 as well as S-100, vimentin and CD68 in P1-S2. C. The FDG PET image demonstrated irregular ring-shaped tracer uptake in the sellar
region (arrow, average SUV 2.58, SUVmax 5.16). Similarly, the DOTATATE PET image highlighted the same ring-shaped somatostatin
receptor expression in the tumors (arrow, average SUV 0.67, SUVmax 1.04). D. H&E staining and MRI of Patient 2. The surgical specimen
exhibited both cartilaginous (P2 cart) and noncartilaginous (P2 noncart) components.
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After surgery, although his vision improved, the
patient died two months later due to disease progression.

in P1-S1 (Figure 2C), indicating that the tumor cells
exhibited a higher degree of proliferation. P1-S2 also
harbored other pathogenic mutations, such as missense
mutations in NCOR1, CREBBP, RPS14 and TERT genes,
and a loss of copy number in PTEN exons 1-9, indicating
that additional genetic alterations were acquired during
disease progression (Figure 2D).
We next asked whether both components from
Patient 2 harbored mutations in either TP53 or PTEN
genes. The targeted NGS revealed no pathogenic TP53
or PTEN gene mutations in either P2 cart or P2 noncart.
NOTCH4 c.[3562G>A] was predicted to be pathogenic
and present in both P2 cart and P2 noncart (Table 2;
Figure 2A, right panel; Figure 2B, right panel). Because
no peripheral blood DNA was available from this patient
as a reference control, we could not determine whether the
shared mutations were germline or somatic. For validation
purposes, sequencing data from Patient 1 samples (P1-S1
and P1-S2) were also analyzed by MuTect v1.1.4 and
Indel by Varscan v2.3.6. The mutations that were called
were almost identical with those from the standard BGI
in-house NGS analysis (Supplementary Table 2).

Patient 2
This patient was a 37-year-old male patient admitted
to a local hospital because of headache, coarsened facial
features and enlarged hands and feet. He had a history
of removal of a growth hormone-secreting pituitary
adenoma by a transcranial approach followed by Gamma
knife radiosurgery (exact dose of radiosurgery not
documented) ten years previous. At the time of admission,
the patient complained of severe cephalalgia and vision
loss in the right eye. This patient was then admitted to
our hospital. MRI revealed a 5.6 x 5.8 x 5.0 cm irregular
cystic mass with ring-enhancement, extending to the
sphenoid sinus, cavernous sinus, clivus, and suprasellar
region (Figure 1D). The patient underwent a transsphenoidal surgery but died three months later. The
postoperative pathologic diagnosis was DDCS consisting
of both cartilaginous (P2 cart) and noncartilaginous
(P2 noncart) components. A sharp boundary was noted
with no transitional zone between the cartilaginous and
noncartilaginous components, resembling the classical
type (Figure 1D). The noncartilaginous spindled tumor
cells were negative for MyoD1, myogenin, and desmin
by immunohistochemical staining (data not shown),
thus excluding the possibility that the noncartilaginous
component was a variant of rhabdomyosarcoma [5].

Combined TP53 and PTEN loss likely resulted
in an increased proliferation index after
radiotherapy
With regard to the pathogenicity, TP53 c.[835delG]
was reported in five carcinoma samples in the Catalogue of
Somatic Mutations in Cancer database. The International
Agency for Research on Cancer (IARC) database for TP53
was investigated, and the codons close to this mutation
were frequently mutated in various types of cancer [17].
The PTEN exon 1-9 region in Patient 1 revealed
normal reads for P1-S1 but reduced reads for P1-S2
(Figure 2D), indicating a PTEN loss in P1-S2. To confirm
this observation, fluorescence in situ hybridization
(FISH) was performed, which showed both heterozygous
and homozygous deletions in P1-S2, with 67% of cells
exhibiting PTEN gene probe loss (11% homozygous
deletions and 56% heterozygous deletions) in randomly
selected fields (Figure 2E).
To test whether the TP53 and PTEN alterations were
related to cell proliferation, we searched for a differently
tested sample on ‘cBioPortal’ (http://www.cbioportal.org/),
which is an open-source, web-based analyzer [18, 19].
One dataset [20] consisting of over two hundred adult soft
tissue sarcomas was analyzed, and the gene encoding the
Ki-67 protein (MKI67) was elevated in 54% of the cases,
all of which displayed a deregulation of either PTEN or
TP53 expression (Figure 2F).
Next, we examined the protein levels of PTEN and
TP53 by immunostaining. Reduced PTEN protein levels
were detected in immunostaining of P1-S2 (Figure 3A)
[21]. Both P1-S1 and P1-S2 harbored the same frameshift
mutation in TP53, which resulted in premature peptide

Sequencing and mutation detections
To address the question of whether the P1-S2 tumor
arose from remnant tumor cells from P1-S1 or arose de
novo, targeted NGS sequencing was conducted for the P1-S1
tissue, P1-S2 tissue and peripheral blood cell DNA. It should
be noted that the P1-S2 tissue that was sequenced consisted
of both cartilaginous and noncartilaginous components
without further micro-dissection, as the cartilaginous
component was interspersed among the noncartilaginous
component and exhibited clear transitional zones in P1-S2.
Targeted NGS sequencing revealed shared frameshift
mutations in TP53 c.[835delG] and three other pathogenic
missense mutations, JAK1 c.[383G>A], MAPK8IP1
c.[1484C>A] and NTRK1 c.[1925C>T], in both P1-S1
and P1-S2, indicating that the tumor sample from the
second surgery (recurrent tumor) was derived from the
residual tissue from the first tumor. Notably, the mutation
frequencies in JAK1, NTRK1, and TP53 increased in P1S2 compared with P1-S1 (Table 1; Figure 2A, left panel;
Figure 2B, left panel). No detectable level of IDH1/2 gene
mutations was found in either P1-S1 or P1-S2, which is
consistent with previous research demonstrating that not all
chondrosarcomas harbor such mutations [9, 16].
Furthermore, both components in P1-S2 (60-80%)
exhibited a considerably increased Ki-67 index compared
with the non-cartilaginous component (less than 3%)
www.impactjournals.com/oncotarget
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Table 1: Sequencing data analyzed by the Standard BGI in-house NGS analysis for Patient 1
Mutation
Mutation
frequencies frequencies
in P1-S1
in P1-S2

cHGVS

pHGVS_ad

Mutation
type

PRX

c.[1687G>A]

p.[A563T]

Missense

4.27

SLC4A1

c.[931C>A]

p.[L311I]

Missense

FAT3

c.[8657A>G]

p.[D2886G]

SPEN

c.[811G>A]

SIK1

Gene name

Condel

Pathogenicity

Not
detectable

0.313

VUS

5.32

Not
detectable

0.477

VUS

Missense

10

Not
detectable

0.319

VUS

p.[G271S]

Missense

11.9

Not
detectable

0.423

VUS

c.[1355C>T]

p.[P452L]

Missense

16.67

Not
detectable

0.523

Pathogenic

NTRK1

c.[1925C>T]

p.[A642V]

Missense

12.5

17.72

0.540

Pathogenic

JAK1

c.[383G>A]

p.[R128H]

Missense

23.53

41.48

N/A

Pathogenic*

MAPK8IP1

c.[1484C>A]

p.[A495D]

Missense

35.71

28.02

0.750

Pathogenic

TP53

c.[835delG]

p.[G279fs*?]

Frameshift

53.12

64.39

N/A

Pathogenic

NCOR1

c.[6591G>C]

p.[K2197N]

Missense

Not
detectable

3.04

0.523

Pathogenic

RAD50

c.[323A>G]

p.[K108R]

Missense

Not
detectable

4.06

0.396

VUS

CREBBP

c.[1974C>G]

p.[I658M]

Missense

Not
detectable

8.87

0.592

Pathogenic

TSHZ3

c.[1804A>T]

p.[M602L]

Missense

Not
detectable

10.36

0.395

VUS

ARHGAP35

c.[3779C>T]

p.[P1260L]

Missense

Not
detectable

14.03

0.442

VUS

RAD52

c.[593C>T]

p.[P198L]

Missense

Not
detectable

18.02

0.467

VUS

NOTCH1

c.[658G>A]

p.[V220M]

Missense

Not
detectable

29.21

0.514

VUS

RPS14

c.[341C>T]

p.[S114L]

Missense

Not
detectable

34.89

0.820

Pathogenic

TERT

c.[901C>T]

p.[R301C]

Missense

Not
detectable

41.02

0.536

Pathogenic

Abbreviations: HGVS: Human Genome Variation Society; P1-S1: Patient-1-surgery-1; P1-S2: Patient-1-surgery-2; VUS:
variants of unknown significance; N/A: Not available.
* SIFT=0.00, Polyphen-2=1.000 for JAK1: c.[383G>A]

The other mutations in Patient 1 were not major
contributors to disease progression

termination and minimal immunostaining for the TP53
protein (Figure 3A). For Patient 2, neither the cartilaginous
nor the noncartilaginous components exhibited TP53 or
PTEN mutations by sequencing. PTEN showed mediumstrong immunostaining intensity in P2 cart and P2 noncart.
TP53 revealed no immunostaining in either component in
Patient 2 (Figure 3A). For quality control purposes, an
adenocarcinoma sample was used as a positive control for
TP53, and lymphocytes were used as a positive control for
PTEN (Figure 3A).
www.impactjournals.com/oncotarget

Because the JAK1 and NTRK1 mutation percentages
were higher in P1-S2 compared with P1-S1, we were
interested in whether these two mutations were accountable
for the increased Ki-67 index. Recent literature has
highlighted the targeting of receptor tyrosine kinases (RTKs)
in human chondrosarcoma. One study [22] on humanderived chondrosarcoma cell lines revealed that targeted
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Figure 2: Targeted NGS showed a combined TP53 and PTEN loss. A. A comparison of the mutation allele frequency in the P1S1 (x-axis) versus those in P1-S2 (y-axis) is shown (left panel). A comparison of the mutation allele frequency in the P2 noncart (x-axis)
versus those in P2 cart (y-axis) is presented (right panel). Shaded areas represent Bayesian posterior probability distributions over mutation
allele frequency in both samples from the same patients. Gray shading indicates mutation allele frequency distributions having considerable
uncertainty, with lighter shading indicating greater uncertainty. Mutations of interest are also labeled. B. Oseq targeted sequencing revealed
both shared and distinct mutations. C. Immunostaining of Ki-67 indexes in surgical specimens from P1-S1, P1-S2 noncart, P1-S2 cart, P2
noncart and P2 cart. D. Schematic view of copy number estimation from the targeted NGS depth data. The copy number of chr10 in the P1S1 sample revealed no copy number changes in the PTEN gene region (locus: 1123~1166) (upper), whereas the copy number of chr10 in the
P1-S2 sample showed alterations in the PTEN gene exon 1-9 region (lower). E. FISH revealed heterozygous and homozygous deletions in
the PTEN gene in P1-S2, with organ probes detecting PTEN and green probes detecting the alpha satellite of 10p11.1-q11.1. F. Schematic
views of the expression levels of MKI67, TP53 and PTEN in a sarcoma dataset.
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Table 2: Sequencing data analyzed by the Standard BGI in-house NGS analysis for Patient 2
cHGVS

pHGVS_ad

Mutation
Mutation
Mutation
frequencies
frequencies
Condel Pathogenicity
type
in P2
in P2 cart
noncart

RAD54L

c.[460C>T]

p.[R154W]

Missense

3.03

Not
detectable

0.749

Pathogenic

NOTCH3

c.[4448G>A]

p.[R1483H]

Missense

3.06

Not
detectable

0.351

VUS

CUL4A

c.[1723C>T]

p.[H575Y]

Missense

3.16

Not
detectable

0.657

Pathogenic

TSC1

c.[1039T>C]

p.[W347R]

Missense

3.24

Not
detectable

0.591

Pathogenic

APC

c.[1678A>G]

p.[K560E]

Missense

3.27

Not
detectable

0.593

Pathogenic

RAD51D

c.[61A>G]

p.[R21G]

Missense

3.29

Not
detectable

0.450

VUS

KMT2A

c.[6415T>C]

p.[Y2139H]

Missense

3.38

Not
detectable

0.543

Pathogenic

FOXA2

c.[69+1G>A]

N/A

Splice-5

3.42

Not
detectable

N/A

VUS

CASP8

c.[319C>T]

p.[R107C]

Missense

3.45

Not
detectable

0.452

VUS

CIC

c.[4634C>T]

p.[A1545V]

Missense

3.52

Not
detectable

0.459

VUS

MEN1

c.[598G>A]

p.[G200S]

Missense

3.62

Not
detectable

0.646

Pathogenic

SMC3

c.[1129G>A]

p.[A377T]

Missense

3.75

Not
detectable

0.617

Pathogenic

KIF5B

c.[2822G>A]

p.[R941H]

Missense

4.07

Not
detectable

0.649

Pathogenic

SPEN

c.[5996A>G]

p.[K1999R]

Missense

4.32

Not
detectable

0.370

VUS

SUZ12

c.[1078C>T]

p.[R360C]

Missense

5.38

Not
detectable

0.448

VUS

ARID1B

c.[2764A>T]

p.[M922L]

Missense

47.88

48.47

0.401

VUS

ARID1B

c.[1025C>T]

p.[A342V]

Missense

45.76

59.26

0.327

VUS

c.[178_179
insCCGCAGCGC]

p.[63_64insAAP]

Cds-indel

31.82

40.58

N/A

VUS

NOTCH4

c.[3562G>A]

p.[D1188N]

Missense

46.77

50.37

0.574

Pathogenic

ATR

c.[982A>G]

p.[M328V]

Missense

87.27

62.56

0.463

VUS

FAT3

c.[10244T>A]

p.[L3415H]

Missense

96.48

77.2

0.321

VUS

c.[16C>A]

p.[P6T]

Missense

Not
detectable

3.17

0.476

VUS

Gene
name

MSH3

EPHA5

(Continued )
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Gene
name

cHGVS

pHGVS_ad

Mutation
Mutation
Mutation
frequencies
frequencies
Condel Pathogenicity
type
in P2
in P2 cart
noncart

FLT4

c.[3106A>G]

p.[R1036G]

Missense

Not
detectable

3.41

0.542

Pathogenic

NOTCH3

c.[458G>A]

p.[R153H]

Missense

Not
detectable

3.52

0.530

Pathogenic

MAPK1

c.[76A>G]

p.[T26A]

Missense

Not
detectable

3.57

0.492

VUS

HDAC6

c.[2764C>T]

p.[Q922*]

Nonsense

Not
detectable

3.7

N/A

VUS*

CUL4B

c.[830A>G]

p.[E277G]

Missense

Not
detectable

4.9

0.527

Pathogenic

MED12

c.[5746C>T]

p.[Q1916*]

Nonsense

Not
detectable

6.25

N/A

Pathogenic

Abbreviations: HGVS: Human Genome Variation Society; P2 cart: Patient 2 cartilaginous component; P2 noncart: Patient 2
noncartilaginous component; VUS: variants of unknown significance; N/A: Not available.
* SIFT=0.25, Polyphen-2=0.557 for HDAC6: c.[2764C>T]
component (Figure 3C). This result suggests that the JAK1
mutation might not be an activating mutation in Patient 1.
We speculated that a TP53-mutated DDCS cancer
cell might lose its surveillance over genomic instability
after radiation, which might have induced a PTEN deletion
in Patient 1. The combined TP53 and PTEN changes
further promoted tumor progression (Figure 3D).

small molecule inhibitors for RTKs slow tumor cell growth.
NTRK1 is a transmembrane protein receptor for nerve
growth factor. After ligand binding, NTRK1 first autophosphorylates at five auto-phosphorylation residues (Y496,
Y676, Y680, Y681, and Y791) and then phosphorylates
downstream molecules, such as p44/42 [23, 24]. Activating
mutations typically result from genomic rearrangements
in papillary thyroid carcinoma and lung cancer [25], and
missense mutations rarely lead to overactivation [23]. The
NTRK1 c.[1925C>T] resulted in a missense mutation of the
NTRK1 protein p.[A642V] in the intracellular domain of
the NTRK1 protein. We were able to visualize the spatial
distances between the four auto-phosphorylated tyrosine
residues and the amino acid change A642V (Figure 3B);
the nearest distance of 23.80Å was between Y680 and
A642V. Thus, the NTRK1 p.[A642V] mutation should not
directly interfere with the phosphorylation process, and
the phospho-p44/42 status should be independent of the
NTRK1 p.[A642V] mutation. Interestingly, phospho-p44/42
exhibited positivity in approximately 45% of the cells of
P1-S1. The staining pattern was not homogenous for this
marker in P1-S2 noncartilaginous component; some areas
exhibited more tumor cells that were positive for this marker
than did others. The average percentage of tumor cells
positive for this marker was 14%. Approximately 55% of
the cells were positive in the P1-S2 cartilaginous component
(Figure 3C). This result suggests that phospho-p44/42 might
not be involved in the tumor progression. In addition, the
JAK1 c.[383G>A] mutation was previously identified in an
endometrial carcinoma sample from the Cancer Genome
Atlas (TCGA) project. Phospho-Stat3, a well-known target
of the JAK1 protein, exhibited positivity in less than 5-8% of
cells in the P1-S1, 3% of cells in the P1-S2 noncartilaginous
component and 6% of cells in the P1-S2 cartilaginous
www.impactjournals.com/oncotarget

DISCUSSION
In this paper, we reported two patients of DDCS
with mutation analysis of selected genes.
The main focus of the current study was to gain
insight into the pathogenesis of disease progression of
DDCS. The mechanism that contributes to the disease
progression from the cartilaginous component to the noncartilaginous sarcomatous component remains unclear.
The present study proposed a mechanism for disease
progression in which combined TP53 and PTEN changes
promote tumor progression in DDCS. Indeed, PTEN
gene mutations are rare in chondrosarcoma, and Lin et
al reported that a PTEN mutation was detected in only
one out of forty chondrosarcoma cases [26]. Alterations
in the PTEN gene are frequently observed after radiation
when TP53 is null or heterozygous in lymphoma [27].
TP53 mutation or loss has been implicated in other types
of sarcoma [28-30]. The concurrent loss of function in
PTEN and TP53 provided an explanation for rapid disease
progression at the time of cancer recurrence for other
tumors, which was also the case for invasive bladder cancer
[31]. In addition, RTK has been reported to be activated
in this type of tumor [22]. However, the NTRK1 mutation
proves not to be an activating mutation in Patient 1.
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Both patients recurred after radiation therapy.
Indeed, only a few cases of DDCS in the skull base have
been reported, including two patients with a history of
prior radiation therapy to the maxillary and frontal bone
regions years before the onset of DDCS [9, 32]. The
first issue is whether radiation ‘induced’ the occurrence
of the dedifferentiated component in DDCS. Our study
cannot answer this question with certainty. In general,
conventional skull base chondrosarcomas respond well
to surgery combined with radiation therapy [33, 34].
However, if the diagnosis is DDCS, then prognosis is poor
Indeed, it is very challenging for a pathologist to make
the diagnosis of DDCS when the cartilaginous component

is absent or unavailable. Patient 1 exhibited nearly no
morphological relevance to chondrosarcoma in the first
surgery, possibly due to incomplete surgical resection,
with only spindle-shaped tumor cells.
Previous studies have suggested that the
noncartilaginous component might derive from the
cartilaginous component with additional mutations. Ropke
et al reported that LOHs of the TP53 and RB genes were
exclusively found in the noncartilaginous component [8].
Terek et al reported that likely-mutated TP53 protein was
accumulated in the noncartilaginous but not cartilaginous
components of DDCS [35]. Grote et al reported a TP53
mutation that occurred exclusively in the noncartilaginous

Figure 3: Combined TP53 and PTEN alterations accounted for disease progression. A. Immunostaining of PTEN and

TP53 in surgical specimens from P1-S1, P1-S2 noncartilaginous component (P1-S2 noncart), P1-S2 cartilaginous component (P1-S2
cart), Patient 2 noncartilaginous component (P2 noncart) and Patient 2 cartilaginous component (P2 cart) (left panel). Positive controls
for TP53 and PTEN were adenocarcinoma and endometrial tumors, respectively (right panel). B. Three-dimensional (3D) structural view
of the NTRK1 protein. The distance from mutated the A642V to the Y676, Y680, Y681, and Y791 residues were 25.48 Å, 23.80 Å, 25.83
Å, and 31.91 Å, respectively. C. Immunostaining of phospho-p44/42 (Thr202/204) and phospho-Stat3 (Tyr705). D. Proposed schematic
illustration of the disease progression due to the combined TP53 and PTEN changes.
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component [11]. Simms et al demonstrated increased TP53
staining in the spindle-cell portion of eight DDCS cases,
whereas all of the cartilaginous components showed weak
or no staining [36]. In our study, the non-cartilaginous
component of P1-S1 shared common mutations in TP53,
JAK1, MAPK8IP1 and NTRK1 in the mixed sample of
P1-S2. However, the P1-S2 sample exhibited additional
mutations in other genes, including a PTEN deletion.
The TP53 immunostaining was negative for both Patient
1 and Patient 2. Patient 1 had a frameshift mutation in
the TP53 gene encoding pre-truncated TP53 proteins,
which explains the negative TP53 immunostaining for
this patient. For Patient 2, we speculate that the wild-type
TP53 protein was low in abundance in comparison with
the positive control and below the detection threshold of
TP53 immunostaining in the current setting.
One major limitation of our study was that the
number of sequenced genes was limited. The targeted
NGS only included the predefined exonic regions of
508 genes. Therefore, epigenetic changes, genomic
rearrangement, and genes outside of that panel could not
be detected. Indeed, one study suggested that both genetic
and epigenetic alterations might occur in DDCS [8].
In conclusion, the present study provided evidence
that the rapid progression and increased Ki-67 index likely
resulted from the concurrent mutations in TP53 and PTEN
genes. The multiple gene alternations detected in the
present study suggest that there might be other molecular
pathways contributing the progression of DDCS as well.

Germany), respectively, according to the manufacturer's
instructions. All FFPE and fresh frozen tissue samples
underwent H&E staining and were reviewed by a
pathologist to ensure > 70% tumor content. DNA purity
and concentration were assessed using a NanoDrop2000
spectrophotometer (Thermo Fisher Scientific, Florida,
USA); DNA quality was assessed by agarose gel
electrophoresis.
Library construction was performed as
previously described using 1 μg of DNA sheared by
an ultrasonoscope to generate fragments with a peak
length of 250 bps, followed by end repair, A tailing and
ligation to the Illumina-indexed adapters according
to the standard library construction protocol. Target
enrichment was performed on a custom sequence captureprobe (Nimblegen, USA), which targeted 7,708 exons of
508 cancer-related genes and 78 introns from 19 genes
recurrently rearranged in solid tumors, representing
approximately 1.7 Mb of the human genome in total
(Supplementary Table 1). Sequencing was performed with
2 x 101-bp paired-end reads and an 8-bp index read on an
Illumina Hiseq 2500 platform (Illumina, San Diego, USA)
using the manufacturer’s protocols.
Primary sequence data were first processed by
filtering adaptor sequences and removing low-quality
reads using the SOAPnuke software developed by BGI
and then aligned to build hg19 of the NCBI reference
genome assembly using the BWA aligner v0.6.2-r126.
Polymerase chain reaction (PCR) duplicate reads were
removed by PICARD v1.98. Local realignment, base
quality score recalibration was performed using GATK
v2.3-9, and poorly mapped reads were removed based on
the recalibration result. SNVs were detected by Standard
BGI in-house NGS analysis SOMATK-SNV (developed
by BGI, manuscript in preparation), and Indels (small
insertions and deletions) were detected by SOMATKINDEL (developed by BGI, manuscript in preparation).
Copy number variation (CNV) calling was performed by
CONTRA v2.0.4. Known SNPs and Indels obtained from
the 1000 Genomes project were discarded. The remaining
variants were subdivided into four categories: (1) variants
that were previously reported to be deleterious; (2)
variants that were likely to be gene-disrupting, including
nonsense and splicing mutations and frameshift caused
by Indels; (3) missense mutations that were judged to be
pathogenic by Condel software [37] and those could not
be predicted by Condel will be predicted by both SIFT and
PolyPhen-2 [38, 39] (SIFT score < 0.05 AND Polyphen-2
score > 0.85); (4) the remaining variants that were
considered as variants of unknown significance (VUS).
The first three categories were defined as pathogenic.
Sanger bidirectional sequencing confirmed the detected
mutations of NTRK1, JAK1, MAPK8IP1 and TP53 in P1S2. For comparison, SNVs were also called by MuTect
v1.1.4 [40], and Indels were called by Varscan v2.3.6 [41].

MATERIALS AND METHODS
Ethical approval
The study protocol was reviewed and approved by
the Ethnical Committee of Peking Union Medical College
Hospital. The two patients provided signed informed
consent to approve the portion of the surgical specimens
for research purposes.
18

F-FDG and 68Ga DOTATATE PET/CT imaging

One patient was IV-injected with 370 MBq of
F-FDG and 120 MBq of 68Ga DOTATATE (a novel
somatostatin analog), respectively. One hour later, the
PET/CT images were acquired using a Siemens Biograph
TruePoint True V PET/CT (Knoxville, TN, USA)
combining 64-slice CT with a supine position.
18

Targeted NGS and validation
Tumor DNA was extracted from formalin-fixed
paraffin-embedded (FFPE) samples and fresh frozen
samples using the QIAamp DNA FFPE Tissue Kit and the
DNEasy Blood and Tissue Extraction Kit (Qiagen, Hilden,
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